MedTrace Logo

Neuroaxial Prophylaxis for CABG

NCT04244435 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2021-09-21

No results posted yet for this study

Summary

Investigators plan to study the effect of thoracic epidural analgesia on postoperative parameters (complication rate, duration of hospitalization, mortality, etc.) of coronary artery bypass grafting.

Conditions

  • Coronary Artery Occlusion

Interventions

PROCEDURE

CABG

coronary artery bypass grafting with and without cardiopulmonary bypass

DRUG

thoracic epidural analgesia

thoracic epidural analgesia at the level of 1-10 thoracic vertebrae (ropivacainum 0,2-0,5% 5-10 ml/h)

DRUG

analgesia of opioids

Opioids will be used for perioperative analgesia

Sponsors & Collaborators

  • Volgograd State Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2020-12-31
Completion
2022-01-31

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04244435 on ClinicalTrials.gov